Pharmaceuticals New Zealand

New Zealand Epigenetics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand Epigenetics Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $22.1 Mn Placeholder estimate
Estimate 2025 $25.3 Mn 1.1% of the global market
Projected 2034 $85.6 Mn 238.3% Adds $60.3 Mn over 9 forecast years
CAGR 2025–2034 14.5% Faster than 73% of 160 Pharmaceuticals markets here
Key players 5 Companies profiled
  • New Zealand is 1.08% of the global market.
  • In APAC, the largest is China at $186.7 Mn.
  • Fastest growing: India at 16.7% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$60.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Epigenetics Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $22.1 Mn — —
2025 (base) $25.3 Mn +$3.2 Mn —
2026 (forecast) $29.0 Mn +$3.7 Mn +14.5%
2027 (forecast) $33.2 Mn +$4.2 Mn +31.1%
2028 (forecast) $38.0 Mn +$4.8 Mn +50.1%
2029 (forecast) $43.5 Mn +$5.5 Mn +71.9%
2030 (forecast) $49.8 Mn +$6.3 Mn +96.8%
2031 (forecast) $57.0 Mn +$7.2 Mn +125.3%
2032 (forecast) $65.3 Mn +$8.3 Mn +158%
2033 (forecast) $74.8 Mn +$9.5 Mn +195.4%
2034 (forecast) $85.6 Mn +$10.8 Mn +238.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.34 Bn
  2. North America $1.12 Bn
  3. US $911.4 Mn
  4. APAC $520.3 Mn
  5. Europe $390.5 Mn
  6. Canada $206.1 Mn
  7. China $186.7 Mn
  8. Japan $137.3 Mn
  9. Latin America $118.7 Mn
  10. Middle East $90.0 Mn
  11. Germany $85.1 Mn
  12. France $63.1 Mn
  13. UK $55.8 Mn
  14. Brazil $57.0 Mn
  15. Italy $50.8 Mn
  16. Ecuador $50.3 Mn
  17. Saudi Arabia $45.7 Mn
  18. Spain $42.0 Mn
  19. India $42.9 Mn
  20. Mexico $37.8 Mn
  21. Africa $34.4 Mn
  22. Russia $26.3 Mn
  23. Australia $25.6 Mn
  24. New Zealand (this report) $25.3 Mn
  25. South Africa $14.4 Mn
  26. UAE $11.9 Mn
  27. Egypt $6.1 Mn
  28. Philippines $5.8 Mn
  29. Malaysia $3.5 Mn
  30. Hong Kong $3.5 Mn
  31. Singapore $2.8 Mn
  32. Thailand $2.6 Mn
  33. Kenya $1.7 Mn

Report snapshot

New Zealand Epigenetics Market Analysis at a glance
Market size, 2025$25.3 Mn placeholder estimate
Forecast, 2034$85.6 Mn placeholder estimate
Growth (CAGR), 2025–203414.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersIllumina, Inc., Thermo Fisher Scientific Inc., Active Motif, Diagenode (Hologic), Zymo Research (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Epigenetics Market Analysis Executive Summary

Epigenetics studies chemical marks on DNA that turn genes on and off, used in research, cancer tests and drug discovery.

Key segments of the epigenetics market include product (Reagents, Kits and Instruments) and application (Oncology, Developmental Biology and Metabolic Diseases).

Bar chart: New Zealand Epigenetics market size, 2024–2034, placeholder estimates. $22.1 Mn in 2024, $25.3 Mn in 2025 and $85.6 Mn in 2034, 14.5% CAGR.
New Zealand Epigenetics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Epigenetics Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the epigenetics market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the epigenetics market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the epigenetics market.

Competitive Landscape for Epigenetics Market in New Zealand

The epigenetics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Epigenetics Market in New Zealand

Epigenetics in New Zealand: rules and payment

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for epigenetics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Epigenetics right now, from free public sources.

Latest research 17,458 papers since 2021 (worldwide)

  1. Epigenetic Allostasis in Alcohol Use Disorder: A Metabolic-Chromatin Framework Linking DNA Methylation, Circuit Remodeling, and Precision Therapeutics. European journal of pharmacology, 2026
  2. Peripheral DNA methylation of candidate Alzheimer's disease risk genes and its associations with cognition, brain volume and amyloid-β burden. Scientific reports, 2026
  3. Epigenetic regulation of DOT1L methyltransferase activityremodels lipid metabolism to alleviate ferroptosis-induced liver injury. The Journal of clinical investigation, 2026
  4. Metabolic and epigenetic programming driving the sequential angiogenic-osteo-/odontogenic differentiation of dental pulp stem cells for regenerative therapy. Molecular biology reports, 2026
  5. Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group. Journal of medicinal chemistry, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Epigenetics in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Epigenetics market in New Zealand?
Placeholder estimate: about $25.3 Mn in 2025, rising to about $85.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Epigenetics market in New Zealand growing?
Placeholder estimate: about 14.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Epigenetics market report cover?
The report splits the market by product (Reagents, Kits, Instruments, Software), application (Oncology, Developmental Biology, Metabolic Diseases, Ageing Research) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Epigenetics market?
Key players include Illumina, Inc., Thermo Fisher Scientific Inc., Active Motif, Diagenode (Hologic) and Zymo Research.
What is driving the Epigenetics market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the epigenetics market.
Who regulates Epigenetics in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How much research is published on Epigenetics?
PubMed lists 17,458 papers on Epigenetics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Epigenetics in New Zealand? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in New Zealand

See all
Same topic, other categories

Related on genomics

See the topic